Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy

• DOI: 10.1016/j.bioactmat.2021.05.036
• Publication Date: 2021-06-05T00:40:58Z
• Authors: Jie Chen; Huapan Fang; Yingying Hu; Jiayan Wu; Sijia Zhang; Yuanji Feng; Lin Lin; Huayu Tian; Xuesi Chen
• Keywords: Cross-Presentation; Nanocarriers; Cancer Immunotherapy

Tumor nanovaccines have potential applications in the prevention and treatment of malignant tumors. However, it remains a longstanding challenge exploiting efficient nanocarriers for inducing potent specifically cellular immune responses. Toward this objective, we herein explore an intensive tumor immunotherapeutic strategy by combining mannosylated gene regulated PD-L1 blockade stimulation killing activity. Here, fabricate mannose modified PLL-RT (Man-PLL-RT) mediated with dendritic cells (DCs) targeting capacity. Man-PLL-RT is capable co-encapsulating antigen (ovalbumin, OVA) adjuvant (unmethylated cytosine-phosphate-guanine, CpG) electrostatic interaction. This positively charged Man-PLL-RT/OVA/CpG can facilitate endocytosis, maturation cross presentation DCs. arouse limited inhibition growth, which mainly due to immunosuppressed microenvironment Combining leads obvious remission B16F10 melanoma bearing mice. The collaborative provides essential insights boost benefits vaccines regulating checkpoint therapy.